keyword
MENU ▼
Read by QxMD icon Read
search

lung cancer, non small cell lung cancer, prognostic markers

keyword
https://www.readbyqxmd.com/read/28534966/microrna-92a-promotes-epithelial-mesenchymal-transition-through-activation-of-pten-pi3k-akt-signaling-pathway-in-non-small-cell-lung-cancer-metastasis
#1
Chaojing Lu, Zhengxiang Shan, Jiang Hong, Lixin Yang
MicroRNAs (miRNAs) have important roles in various cancers, including non-small cell lung cancer (NSCLC). Although several miRNAs have reported to be involved in the development of NSCLC, understanding the regulatory roles of other miRNAs in NSCLC is essential. Therefore, the aim of the current study was to explore the roles and mechanisms of screened miRNAs in NSCLC. First, the differentially expressed miRNAs that were screened based on GSE29248 microarray data retrieved from Gene Expression Omnibus (GEO)...
May 16, 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/28533476/neutrophil-lymphocyte-ratio-is-a-prognostic-marker-in-patients-with-locally-advanced-stage-iiia-and-iiib-non-small-cell-lung-cancer-treated-with-combined-modality-therapy
#2
Katherine A Scilla, Søren M Bentzen, Vincent K Lam, Pranshu Mohindra, Elizabeth M Nichols, Melissa A Vyfhuis, Neha Bhooshan, Steven J Feigenberg, Martin J Edelman, Josephine L Feliciano
BACKGROUND: Neutrophil-lymphocyte ratio (NLR) is a measure of systemic inflammation that appears prognostic in localized and advanced non-small cell lung cancer (NSCLC). Increased systemic inflammation portends a poorer prognosis in cancer patients. We hypothesized that low NLR at diagnosis is associated with improved overall survival (OS) in locally advanced NSCLC (LANSCLC) patients. PATIENTS AND METHODS: Records from 276 patients with stage IIIA and IIIB NSCLC treated with definitive chemoradiation with or without surgery between 2000 and 2010 with adequate data were retrospectively reviewed...
May 22, 2017: Oncologist
https://www.readbyqxmd.com/read/28521472/cd117-expression-is-a-predictive-marker-for-poor-prognosis-in-patients-with-non-small-cell-lung-cancer
#3
Tomohiko Sakabe, Junya Azumi, Tomohiro Haruki, Yoshihisa Umekita, Hiroshige Nakamura, Goshi Shiota
Non-small cell lung cancer (NSCLC) accounts for >85% of incidences of lung cancer, for which the predicted 5-year survival rates are low and recurrence rates remain high. Although it has been reported that the patients with SCLC cells that possess the cluster of differentiation (CD) 117 marker exhibited poor prognosis and poor response to chemotherapy, no studies concerning the association of CD117 expression with prognosis of the patients with NSCLC have been reported. An in vitro study reportedly revealed that CD117-positive cell populations in NSCLC cell lines exhibited cancer stem cell (CSC) phenotypes including self-renewal and chemoresistance...
May 2017: Oncology Letters
https://www.readbyqxmd.com/read/28515924/effect-of-serum-interleukin-1-receptor-antagonist-level-on-survival-of-patients-with-non-small-cell-lung-cancer
#4
Murat Yigit, Serkan Değirmencioğlu, Erhan Ugurlu, Arzu Yaren
Due to poor prognosis in advanced non-small cell lung cancer (NSCLC), new effective markers are required in the monitoring of the disease. The present study aimed to investigate the association between the serum IL-1 receptor antagonist (IL-1Ra) level, overall survival (OS), and treatment response in NSCLC, and to evaluate the usefulness of the serum IL-1Ra level as a prognostic marker for NSCLC. Eighty patients (72 men and 8 women) and 40 healthy volunteers (13 men and 27 women) were included in the present study...
May 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28514746/diagnostic-and-prognostic-values-of-endothelial-cell-specific-molecule-1-with-malignant-pleural-effusions-in-patients-with-non-small-cell-lung-cancer
#5
Guo-Jun Lu, Cheng-Jie Shao, Yu Zhang, Yong-Yue Wei, Wei-Ping Xie, Hui Kong
Over-expressed endothelial-cell-specific molecule-1 (ESM-1) in tumor vascular endothelium contributes to tumor angiogenesis, metastasis, and poor prognosis. However, the content of ESM-1 in pleural effusion is unclear. A retrospective study was carried out to investigate the diagnostic and prognostic values of ESM-1 with malignant pleural effusions in patients with non-small cell lung cancer (NSCLC). ESM-1 levels in malignant pleural effusion (MPE) from 70 patients with NSCLC and 50 cases of benign pleural effusion (BPE) were measured using enzyme-linked immunosorbent assay...
April 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/28499650/the-mesenchymal-state-predicts-poor-disease-free-survival-in-resectable-non-small-cell-lung-cancer
#6
Kunal Mehta, Erika Moravcikova, David McFall, James D Luketich, Arjun Pennathur, Albert D Donnenberg, Vera S Donnenberg
BACKGROUND: The epithelial-mesenchymal transition (EMT) is thought to contribute to the overall invasiveness of malignant cells. Expression of cluster of differentiation (CD) 44 and CD90 mark the mesenchymal state in multiple epithelial malignancies. Their role in lung cancer remains unclear, however. This study evaluated the prognostic significance of CD44 and CD90 coexpression in patients with resectable primary non-small cell lung cancer (NSCLC). METHODS: This was a nonconcurrent cohort study of patients with resectable NSCLC, stratified by the degree of expression of CD44/CD90 double-positive cells in their primary tumor...
May 9, 2017: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/28497423/validation-of-the-prognostic-value-of-new-sub-stages-within-the-ajcc-8th-edition-of-non-small-cell-lung-cancer
#7
O Abdel-Rahman
BACKGROUND: The 8th edition of the American Joint Committee on Cancer (AJCC) staging system for non-small cell lung cancer (NSCLC) has been released. The current study tried to validate the prognostic significance of the new system among patients registered within the surveillance, epidemiology and end results (SEER) database. METHODS: SEER database (2010-2013) has been accessed through SEER*Stat program and AJCC 8th edition stages were reconstructed utilizing the collaborative stage descriptions...
May 11, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28490471/analysis-of-prognostic-values-of-various-pet-metrics-in-preoperative-fdg-pet-for-early-stage-bronchial-carcinoma-for-progression-free-and-overall-survival-significantly-increased-glycolysis-is-a-predictive-factor
#8
Seraina Steiger, Michael Arvanitakis, Beate Sick, Walter Weder, Sven Hillinger, Irene A Burger
Purpose: To assess various volume based PET quantification metrics including: metabolic tumor volume (MTV) and total lesion glycolysis (TLG) with different thresholds as well as background activity based PET metrics (Background Subtracted Lesion activity (BSL) and Volume (BSV)) as prognostic markers for progression free and overall survival (PFS, OS) in early stage I and II non-small cell lung cancer (NSCLC) after resection. Patients and Methods: 133 patients received an adequate FDG PET/CT scan prior to surgery between January 2003 and December 2010...
May 10, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28487765/the-long-term-prognosis-of-induction-chemotherapy-followed-by-surgery-for-n2-non-small-cell-lung-cancer-a-retrospective-case-series-study
#9
Naohiro Taira, Hidenori Kawasaki, Tomonori Furugen, Takaharu Ichi, Kazuaki Kushi, Tomofumi Yohena, Tsutomu Kawabata
INTRODUCTION: The long-term prognosis of induction chemotherapy followed by surgery for N2 non-small lung cell cancer (NSCLC) remains controversial. PATIENTS AND METHODS: We retrospectively reviewed the data and assessed the prognosis of 31 N2-NSCLC patients who underwent induction chemotherapy followed by surgery at our institution between January 1999 and December 2013. Potential prognostic factors, such as age, gender, tumor histology, tumor marker levels, tumor size, the number of N2 lymph nodes, the time from the last induction chemotherapy to the date of surgery, induction chemotherapy, RECIST response, downstaging status, pathological stage, adjuvant chemotherapy, and EF, were analyzed...
May 2017: Annals of Medicine and Surgery
https://www.readbyqxmd.com/read/28474575/circulating-tumor-cells-predict-prognosis-following-tyrosine-kinase-inhibitor-treatment-in-egfr-mutant-non-small-cell-lung-cancer-patients
#10
Baohong Yang, Aiying Qin, Kongyuan Zhang, Haipeng Ren, Shuzhen Liu, Xiaolei Liu, Xiangpo Pan, Guohua Yu
Epithelial growth factor receptor (EGFR) mutations are present in 10-26% of non-small-cell lung cancer (NSCLC) tumors and are associated with response to tyrosine kinase inhibitors (TKIs). This study aimed to detect and quantify the presence of circu-lating tumor cells (CTCs) in EGFR-mutant NSCLC patients and investigate their possi-ble role in providing prognostic information. Enrolled patients received erlotinib 150 mg or gefitinib 250 mg orally once daily as first line treatment. Serial blood samples were taken at baseline (CTC-d0), and on day 28 (CTC-d28) following the initiation of erlo-tinib/gefitinib for detection of CTCs using the CellSearch system...
April 25, 2017: Oncology Research
https://www.readbyqxmd.com/read/28469508/effects-of-serum-leptin-and-resistin-levels-on-cancer-cachexia-in-patients-with-advanced-stage-non-small-cell-lung-cancer
#11
Gökcen Demiray, Serkan Değirmencioğlu, Erhan Uğurlu, Arzu Yaren
INTRODUCTION: Cancer cachexia is one of the most frequent effects of malignancy, is often associated with poor prognosis, and may account for up to 20% of cancer deaths. The aim of our study was to evaluate the relationship of cancer cachexia and serum levels of resistin and leptin in patients with advanced non-small cell lung cancer. METHODS: A total of 67 chemotherapy-naïve patients with advanced-stage non-small cell cancer and a control group containing 20 healthy individuals without a known chronic disease were enrolled in this study...
2017: Clinical Medicine Insights. Oncology
https://www.readbyqxmd.com/read/28459197/predictive-and-prognostic-value-of-serum-periostin-in-advanced-non-small-cell-lung-cancer-patients-receiving-chemotherapy
#12
Yan Zhang, Dongmei Yuan, Yanwen Yao, Wenkui Sun, Yi Shi, Xin Su
Periostin is an extracellular matrix protein involved in tumorigenesis and metastasis. However, the role of serum periostin as a surrogate marker for treatment efficacy is still unknown. In 122 advanced non-small cell lung cancer cases, 37 patients with benign lung disease and 40 healthy controls, serum periostin was measured by enzyme-linked immunosorbent assays. The associations of serum periostin levels with the clinic-pathological parameters, chemotherapy response, and clinical outcomes of non-small cell lung cancer patients were analyzed...
May 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28454298/expression-and-prognostic-relevance-of-mage-a3-and-mage-c2-in-non-small-cell-lung-cancer
#13
Xinfeng Chen, Liping Wang, Jinyan Liu, Lan Huang, Li Yang, Qun Gao, Xiaojuan Shi, Jieyao Li, Feng Li, Zhen Zhang, Song Zhao, Bin Zhang, Pierre Van der Bruggen, Yi Zhang
Melanoma-associated antigen (MAGE)-A3 and MAGE-C2 are antigens encoded by cancer-germline genes, and have been recognized as potential prognostic biomarkers and attractive targets for immunotherapy in multiple types of cancer. The present study aimed to analyze the clinicopathological significance of MAGE-A3/C2 expression in non-small cell lung cancer (NSCLC). The association between MAGE-A3/C2 mRNA and protein expression, and the pathological characteristics and overall survival of patients with NSCLC was analyzed...
March 2017: Oncology Letters
https://www.readbyqxmd.com/read/28453703/heart-dose-exposure-as-prognostic-marker-after-radiotherapy-for-resectable-stage-iiia-b-non-small-cell-lung-cancer-secondary-analysis-of-a-randomized-trial
#14
M Guberina, W Eberhardt, M Stuschke, T Gauler, F Heinzelmann, D Cheufou, M Kimmich, G Friedel, H Schmidberger, K Darwiche, V Jendrossek, M Schuler, G Stamatis, C Pöttgen
Background: Heart exposure to ionizing irradiation can cause ischaemic heart disease. The partial heart volume receiving ≥5 Gy (heartV5) was supposed to be an independent prognostic factor for survival after radiochemotherapy for locally advanced non-small-cell lung cancer (NSCLC). But validation of the latter hypothesis is needed under the concurrent risks of lung cancer patients. Patients and methods: The ESPATUE phase III trial recruited patients with potentially operable IIIA(N2)/selected IIIB NSCLC between 01/2004 and 01/2013...
May 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28445945/non-small-cell-lung-cancer-associated-microrna-expression-signature-integrated-bioinformatics-analysis-validation-and-clinical-significance
#15
Chunyu Li, Yunhong Yin, Xiao Liu, Xuejiao Xi, Weixiao Xue, Yiqing Qu
Recently, increasing studies of miRNA expression profiling has confirmed that miRNA plays an essential role in non-small cell lung cancer (NSCLC). However, inconsistent or discrepant results exist in these researches. In present study, we performed an integrative analysis of 32 miRNA profiling studies compared the differentially expressed miRNA between NSCLC tissue and non-cancerous lung tissue to identify candidate miRNAs associated with NSCLC. 7 upregulated and 10 downregulated miRNAs were identified as miRNA integrated-signature using Robust Rank Aggregation (RRA) method...
April 11, 2017: Oncotarget
https://www.readbyqxmd.com/read/28445149/elevated-cd147-expression-is-associated-with-shorter-overall-survival-in-non-small-cell-lung-cancer
#16
Xiaojun Zhang, Tian Tian, Xiaofeng Zhang, Changting Liu, Xiangqun Fang
A number of studies have reported on the prognostic role of CD147 expression in non-small cell lung cancer (NSCLC); however, the results remain controversial. This study aims to investigate the impact of CD147 on the prognosis of NSCLC by means of a meta-analysis. A literature search was performed for relevant studies published before October 29, 2016. The hazard ratios (HRs), odds ratios (ORs), and 95% confidence intervals (CIs) were calculated as effective measures. Sensitivity analysis and publication bias examination were also conducted...
April 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28407465/kras-g12c-mutation-as-a-poor-prognostic-marker-of-pemetrexed-treatment-in-non-small-cell-lung-cancer
#17
Sehhoon Park, Ji-Yeon Kim, Se-Hoon Lee, Beomseok Suh, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo
BACKGROUND/AIMS: The predictive and prognostic value of KRAS mutation and its type of mutations in non-small cell lung cancer (NSCLC) are controversial. This clinical study was designed to investigate the predictive value of KRAS mutations and its mutation types to pemetrexed and gemcitabine based treatment. METHODS: Advanced NSCLC patients tested for KRAS mutation (n = 334) were retrospectively reviewed and 252 patients with wild type epidermal growth factor receptor and no anaplastic lymphoma kinase fusion were enrolled for the analysis...
May 2017: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/28404927/prognostic-role-of-b7-h4-in-patients-with-non-small-cell-lung-cancer-a-meta-analysis
#18
Zhibo Tan, Weixi Shen
B7 homolog 4 (B7-H4) has been recently reported to be a prognostic marker in non-small cell lung cancer (NSCLC) in some studies. However, the results remained conflicting. Thus, we aimed to comprehensively assess the association between B7-H4 expression and prognosis of NSCLC patients by performing a meta-analysis. Relevant publications were thoroughly searched of PubMed, Embase, Web of Science and China National Knowledge Infrastructure (CNKI). The pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs) were applied to evaluate the effects...
April 18, 2017: Oncotarget
https://www.readbyqxmd.com/read/28386364/nestin-servers-as-a-promising-prognostic-biomarker-in-non-small-cell-lung-cancer
#19
Fang Liu, Yuan Zhang, Ming Lu, Cong Wang, Qingbao Li, Yongsheng Gao, Dianbin Mu, Yan Cao, Miaomiao Li, Xiangjiao Meng
Lung cancer is currently the leading cause of cancer-related death worldwide and it is important to identify the predictive and/or prognostic markers for the cancer. Nestin, a proliferative and multipotent biomarker has been reported to be associated with prognosis in non-small cell lung cancer (NSCLC) in a few studies. In the present study, we retrospectively recruited 153 patients with NSCLC. Nestin protein expression in tumor samples was determined by immunohistochemistry staining. Nestin expression was related with tumor differentiation (P=0...
2017: American Journal of Translational Research
https://www.readbyqxmd.com/read/28368395/mutant-p53-upregulates-alpha-1-antitrypsin-expression-and-promotes-invasion-in-lung-cancer
#20
R Shakya, G A Tarulli, L Sheng, N A Lokman, C Ricciardelli, K I Pishas, C I Selinger, M R J Kohonen-Corish, W A Cooper, A G Turner, P M Neilsen, D F Callen
Missense mutations in the TP53 tumor-suppressor gene inactivate its antitumorigenic properties and endow the incipient cells with newly acquired oncogenic properties that drive invasion and metastasis. Although the oncogenic effect of mutant p53 transcriptome has been widely acknowledged, the global influence of mutant p53 on cancer cell proteome remains to be fully elucidated. Here, we show that mutant p53 drives the release of invasive extracellular factors (the 'secretome') that facilitates the invasion of lung cancer cell lines...
April 3, 2017: Oncogene
keyword
keyword
80881
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"